A detailed history of Daiwa Securities Group Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 215 shares of PTGX stock, worth $9,855. This represents 0.0% of its overall portfolio holdings.

Number of Shares
215
Previous 215 -0.0%
Holding current value
$9,855
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

BUY
$21.79 - $32.15 $1,133 - $1,671
52 Added 31.9%
215 $6,000
Q3 2021

Nov 05, 2021

BUY
$12.95 - $49.69 $1,061 - $4,074
82 Added 101.23%
163 $3,000
Q4 2020

Feb 04, 2021

SELL
$18.49 - $25.13 $2,126 - $2,889
-115 Reduced 58.67%
81 $2,000
Q3 2020

Nov 02, 2020

BUY
$15.19 - $22.4 $637 - $940
42 Added 27.27%
196 $4,000
Q4 2019

Jan 31, 2020

BUY
$4.69 - $13.45 $722 - $2,071
154 New
154 $1,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.